Giredestrant plus palbociclib shows limited benefit in ER-positive, HER2-negative metastatic breast cancer
Prof Eleftherios Mamounas talks to ecancer at ESMO 2026 about the final analysis of the phase III NSABP B-42 trial, evaluating extended adjuvant letrozole in postmenopausal women with hormone receptor-positive breast cancer.
The study randomised 3,966 patients who had completed five years of endocrine therapy to receive an additional five years of letrozole or placebo.
After a median follow-up of 15.9 years, extended letrozole significantly improved disease-free survival (61.6% versus 56.5%; HR 0.85), reduced distant recurrence (6.9% versus 9.7%) and improved breast cancer-free interval.
However, no significant overall survival benefit was observed (HR 0.92).
The findings demonstrate a sustained benefit from extended letrozole therapy, with no attenuation of treatment effect between 10 and 15 years of follow-up.
Giredestrant plus palbociclib shows limited benefit in ER-positive, HER2-negative metastatic breast cancer
Sacituzumab govitecan improves PFS across Trop-2, BRCA, and HER2 metastatic triple-negative breast cancer
Sacituzumab govitecan plus pembrolizumab improves PFS across biomarker subgroups in metastatic triple-negative breast cancer
FX-909 shows tumour regression in PPARG-high advanced urothelial carcinoma
Omitting sentinel lymph node biopsy is safe in early HR-positive, HER2-negative breast cancer after 5 years
Sacituzumab govitecan improves PFS in first-line metastatic TNBC patients unable to receive PD-(L)1 inhibitors
177Lu-PSMA-617 in metastatic castration-resistant prostate cancer shows higher PSA response with lower toxicity
Targeted therapies associated with increased risk for and incidence of thrombosis in the treatment of breast cancer
HER3-DXd demonstrates similar efficacy compared to multi-agent chemotherapy in high-risk HR-positive/HER2-negative eBC